Evidence map›Paper›PMID 33044914›Full record

ArticleCancer biology & therapy2020

Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and

Ricardo E Perez, Sarah Calhoun, Daeun Shim, Victor V Levenson, Lei Duan, Carl G Maki

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Investigating the oncogenic potential of MTHFD2 in oral squamous cell carcinoma.Journal of cancer research and clinical oncology · 2026
    Article
  2. A novel role of secreted methionine adenosyltransferase α2 in colorectal liver metastases.Journal of experimental & clinical cancer research : CR · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ricardo E PerezDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Sarah CalhounDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Daeun ShimDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Victor V LevensonDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Lei DuanDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Carl G MakiDepartment of Cell and Molecular Medicine, Rush University Medical Center , Chicago, IL, USA.
Rush University Medical Center · US

Funding

Targeting Prolyl Peptidases in Tamoxifen Resistant Breast CancerR01CA200232 · NCI · RUSH UNIVERSITY MEDICAL CENTER · PI MAKI, CARL G · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA200232
6 · The paper itself

Abstract

Prolyl endopeptidase (PREP), also known as prolyl oligopeptidase (POP), is an enzyme that cleaves short peptides (<30 amino acids in length) on the C-terminal side of proline. PREP is highly expressed in multiple carcinomas and is a potential target for cancer therapy. A potent inhibitor of PREP, Y-29794, causes long-lasting inhibition of PREP in mouse tissues. However, there are no reports on Y-29794 effects on cancer cell and tumor proliferation. Using cell line models of aggressive triple-negative breast cancer (TNBC), we show here that Y-29794 inhibited proliferation and induced death in multiple TNBC cell lines. Cell death induced by Y-29794 coincided with inhibition of the IRS1-AKT-mTORC1 survival signaling pathway, although stable depletion of PREP alone was not sufficient to reduce IRS1-AKT-mTORC1 signaling or induce death. These results suggest that Y-29794 elicits its cancer cell killing effect by targeting other mechanisms in addition to PREP. Importantly, Y-29794 inhibited tumor growth when tested in xenograft models of TNBC in mice. Induction of cell death in culture and inhibition of xenograft tumor growth support the potential utility of Y-29794 or its derivatives as a treatment option for TNBC tumors.

Indexed as

AnimalsDisease Models, AnimalHumansInsulin Receptor Substrate ProteinsMiceMice, NudeProlyl OligopeptidasesProto-Oncogene Proteins c-aktTransfectionTriple Negative Breast NeoplasmsInsulin Receptor Substrate ProteinsIRS1 protein, humanProlyl OligopeptidasesProto-Oncogene Proteins c-aktIRS1-AKT-mTORC1 pathwayProlyl endopeptidasetriple-negative breast cancer

Identifiers

PMID33044914
PMCPMC7678932
OpenAlexW3091923043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.